DENVER — Use of nonaspirin NSAIDs more than twice per week was associated with a 45% reduction in the risk of developing bladder cancer in a pooled analysis of three prospective cohort studies totaling more than half a million subjects.
The strongest inverse association was seen with daily use, which conferred a 50% reduction in bladder cancer risk among nonsmokers after adjustment for sex, smoking status, body mass index, race, and aspirin use, Sarah Daugherty, Ph.D., reported at the annual meeting of the American Association for Cancer Research.
The use of aspirin proved to be unrelated to bladder cancer risk in this pooled analysis, added Dr. Daugherty of the National Cancer Institute.
The three prospective cohort studies incorporated in this analysis were the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, the NIH-AARP Diet and Health Study, and the U.S. Radiologic Technologist Health Study.
Together the three cohorts totaled 508,807 adults, of whom 2,553 developed bladder cancer during a median of 7 years of follow-up.